Eiger BioPharmaceuticals, Inc.
EIGRQ · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $10 | $49 | $176 | $346 |
| - Cash | $25 | $26 | $22 | $29 |
| + Debt | $41 | $40 | $33 | $33 |
| Enterprise Value | $26 | $64 | $186 | $350 |
| Revenue | $16 | $13 | $12 | $0 |
| % Growth | 17% | 11.1% | – | – |
| Gross Profit | $15 | $11 | $11 | -$1 |
| % Margin | 95.1% | 80.1% | 87.3% | – |
| EBITDA | -$69 | -$92 | -$29 | -$62 |
| % Margin | -435.8% | -681.5% | -242.9% | – |
| Net Income | -$75 | -$97 | -$34 | -$65 |
| % Margin | -475.3% | -717.7% | -279.3% | – |
| EPS Diluted | -50.78 | -69.74 | -29.98 | -69.34 |
| % Growth | 27.2% | -132.6% | 56.8% | – |
| Operating Cash Flow | -$75 | -$83 | -$72 | -$63 |
| Capital Expenditures | -$0 | -$0 | -$49 | -$0 |
| Free Cash Flow | -$75 | -$83 | -$120 | -$63 |